EMEA-001220-PIP05-19
Key facts
| Invented name |
Olumiant
|
| Active substance |
Baricitinib
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0070/2020
|
| PIP number |
EMEA-001220-PIP05-19
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Eli Lilly & Company Limited
Tel. +44 (0)1276 483000 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|